Key result
MicroRNAs show diagnostic and therapeutic potential for diabetic cardiomyopathy by targeting critical molecular pathways.
Why the study?
Diabetic cardiomyopathy manifests symptoms at a late stage when heart failure risk is high, prompting exploration of microRNAs to study pathophysiology and devise treatments.
MicroRNAs represent a promising tool for understanding the pathophysiology and developing sustainable treatments for diabetic cardiomyopathy.
MicroRNA-based diagnostics and therapies may warrant exploration in diabetic cardiomyopathy; leaves open prospective clinical validation.
MicroRNAs have emerged as an important regulator of post-transcriptional gene expression studied extensively in many cancers, fetal development, and cardiovascular diseases. Their endogenous nature and easy manipulation have made them potential diagnostic and therapeutic molecules. Diseases with complex pathophysiology such as Diabetic Cardiomyopathy display symptoms at a late stage when the risk of heart failure has become very high. Therefore, the utilization of microRNAs as a tool to study pathophysiology and device-sustainable treatments for DCM could be considered. The present review focuses on the mechanistic insights of diabetic cardiomyopathy and the potential role of microRNAs.
No takes yet. Share an insight, caveat, or question.
Mathur et al. (2024) conducted a review in Diabetic Cardiomyopathy. MicroRNAs was evaluated. MicroRNAs show potential as diagnostic and therapeutic molecules for diabetic cardiomyopathy by targeting critical molecular pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: